Endo International PLC (NASDAQ:ENDP)‘s stock had its “buy” rating reaffirmed by investment analysts at Mizuho in a research note issued on Thursday. They presently have a $19.00 target price on the stock. Mizuho’s price objective would indicate a potential upside of 139.29% from the company’s previous close.

Several other brokerages also recently weighed in on ENDP. Zacks Investment Research raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, May 2nd. ValuEngine downgraded shares of Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research note on Tuesday. Deutsche Bank AG cut their target price on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, July 7th. Finally, BMO Capital Markets reissued a “hold” rating and issued a $16.00 target price on shares of Endo International PLC in a research note on Wednesday, May 17th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $16.02.

Shares of Endo International PLC (NASDAQ:ENDP) opened at 7.94 on Thursday. The stock has a 50 day moving average of $11.36 and a 200 day moving average of $11.72. Endo International PLC has a 12-month low of $7.81 and a 12-month high of $24.93. The stock’s market capitalization is $1.77 billion.

Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. During the same quarter in the previous year, the company posted $0.86 EPS. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. Equities research analysts anticipate that Endo International PLC will post $3.53 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/10/endo-international-plcs-endp-buy-rating-reaffirmed-at-mizuho.html.

Several hedge funds have recently modified their holdings of ENDP. HL Financial Services LLC boosted its stake in shares of Endo International PLC by 1.0% in the second quarter. HL Financial Services LLC now owns 52,800 shares of the company’s stock worth $590,000 after buying an additional 500 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after buying an additional 619 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after buying an additional 677 shares during the last quarter. Capstone Asset Management Co. boosted its stake in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after buying an additional 960 shares during the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Endo International PLC by 1.5% in the second quarter. Arizona State Retirement System now owns 83,700 shares of the company’s stock worth $935,000 after buying an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 93.00% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.